title: Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma.
abstract: We investigated the feasibility of local treatment or tumor vaccination with a herpes simplex virus (HSV) type 1-defective vector. The vector was engineered to express murine interferon-gamma (IFN-gamma) for experimental gene therapy against mouse glioma Rous sarcoma virus (RSV). The murine IFN-gamma gene was driven by the cytomegalovirus promoter. The helper virus (tsk) was thermosensitive; consequently, this vector could only proliferate at 31 degrees C. A high level of murine IFN-gamma expression was confirmed in vitro and in vivo by immunohistochemistry using anti-mouse IFN-gamma monoclonal antibody. This engineered vector (dvHSV/MulFN-gamma) inhibited the proliferation of mouse glioma RSV cells in vitro, and an intratumoral (i.t.) local injection of the vector caused i.t. necrosis in vivo. The immunological effect of dvHSV/MulFN-gamma was also examined in a mouse glioma RSV cell implantation model. A subcutaneous (s.c.) implant of 1 x 10(6) mouse glioma RSV cells after treatment with dvHSV/MulFN-gamma was rejected. However, the implant after treatment with an engineered HSV-defective vector containing an antisense nucleotide sequence of the murine IFN-gamma gene was not rejected. In addition, in another group of mice in which RSV cells treated with dvHSV/MulFN-gamma were implanted into a femoral (s.c.) region and nontreated RSV cells were implanted into a contralateral femoral (s.c.) region, the implanted RSV cells were rejected. The rejection of the implanted mouse glioma RSV was blocked by anti-asialo GM1, which was known to inhibit natural killer cell activity. These results revealed that the HSV-defective vector could realize a high efficiency of transfection to glioma cells through short-time treatment, and that the IFN-gamma gene transferred to the cells had the effect of tumor vaccination, which was suggested be related to natural killer cells. In conclusion, dvHSV/MulFN-gamma may be useful for the gene therapy of malignant glioma through either i.t. local injection or a practical tumor vaccination with ex vivo gene transfer.
authors: Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan. kanno@med.yokohama-cu.ac.jp
authors: H
authors: H
authors: Kanno
authors: S
authors: S
authors: Hattori
authors: H
authors: H
authors: Sato
authors: H
authors: H
authors: Murata
authors: F H
authors: FH
authors: Huang
authors: A
authors: A
authors: Hayashi
authors: N
authors: N
authors: Suzuki
authors: I
authors: I
authors: Yamamoto
authors: S
authors: S
authors: Kawamoto
authors: M
authors: M
authors: Minami
authors: S
authors: S
authors: Miyatake
authors: T
authors: T
authors: Shuin
authors: M G
authors: MG
authors: Kaplitt
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D003673:Defective Viruses / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D007371:Interferon-gamma / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D018139:Simplexvirus / Q000378:metabolism*; D013997:Time Factors; D014709:Vero Cells
chemical_list: D007371:Interferon-gamma